Quick Answer
vTv Therapeutics Inc. reported Operating Income Loss of -$32.81 million for the year ending 2025.
- vTv Therapeutics Inc. showed a decrease of -35.7% in Operating Income Loss from 2024 to 2025.
- This data is from vTv Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on March 10, 2026.
- XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2014: -$9.52 million | Q2 2014: -$7.19 million | Q3 2014: -$5.52 million | Q4 2014: -$6.67 million | Q1 2015: -$9.72 million | Q2 2015: -$7.89 million | Q3 2015: -$9.44 million | Q4 2015: -$11.09 million | Q1 2016: -$13.54 million | Q2 2016: -$14.64 million | Q3 2016: -$13.53 million | Q4 2016: -$13.31 million | Q1 2017: -$13.75 million | Q2 2017: -$12.62 million | Q3 2017: -$11.54 million | Q4 2017: -$12.77 million | Q1 2018: -$9.13 million | Q2 2018: -$8.86 million | Q3 2018: -$1.48 million | Q4 2018: -$351.0 thousand | Q1 2019: -$4.29 million | Q2 2019: -$4.79 million | Q3 2019: -$5.43 million | Q4 2019: -$6.39 million | Q1 2020: -$6.65 million | Q2 2020: -$4.20 million | Q3 2020: -$2.83 million | Q1 2021: -$4.28 million | Q2 2021: -$4.67 million | Q3 2021: -$1.60 million | Q1 2022: -$6.48 million | Q2 2022: -$4.03 million | Q3 2022: -$5.69 million | Q1 2023: -$7.43 million | Q2 2023: -$8.00 million | Q3 2023: -$5.37 million | Q1 2024: -$5.63 million | Q2 2024: -$7.16 million | Q3 2024: -$6.51 million | Q1 2025: -$6.50 million | Q2 2025: -$7.72 million | Q3 2025: -$10.70 million.
- Over the full 13 years of available data (2013 to 2025), vTv Therapeutics Inc.'s Operating Income Loss has grown by 8.4%.
- Historical annual values: Fiscal year 2025: -$32.81 million | Fiscal year 2024: -$24.18 million | Fiscal year 2023: -$25.50 million | Fiscal year 2022: -$22.54 million | Fiscal year 2021: -$21.66 million | Fiscal year 2020: -$11.85 million | Fiscal year 2019: -$20.89 million | Fiscal year 2018: -$19.82 million | Fiscal year 2017: -$50.68 million | Fiscal year 2016: -$55.02 million | Fiscal year 2015: -$38.14 million | Fiscal year 2014: -$28.90 million | Fiscal year 2013: -$35.83 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: